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Abstract. Acquired Immunodeficiency Syndrome (AIDS) was first known in 1981 in 
homosexual groups who had opportunistic infections and malignancies. In Indonesia the 
first AIDS case was reported in 1987 to a Dutch citizen living in the province of Bali. Cases 
of HIV infection in Indonesia are reported to increase every year and most occur at the age 
of 25-49 years. HIV transmission is not easily transmitted, even when an HIV-infected 
person takes antiretroviral drugs can reduce the risk of transmission by up to 96%. But one 
of the biggest challenges in managing HIV infection is facing stigma and discrimination. 
As many as 1 in 5 people living with HIV are afraid to come to the clinic because they will 
experience discrimination and stigma from the community if this condition occurs will 
cause treatment delay until PLWHA (People living with HIV/AIDS) will fall to the AIDS 
stage and PLWHA will be susceptible to opportunistic infections. A clinic in Namibia, 
when stigma and discrimination were successfully overcome, there was a 20% reduction in 
mortality in PLWHA. 
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Abstrak.  Acquired Immunodeficiency Syndrome (AIDS) pertama kali dikenal pada tahun 
1981 pada kelompok homoseksual yang mengalami infeksi oportunistik dan keganasan. Di 
Indonesia kasus AIDS pertama kali dilaporkan pada tahun 1987 pada seorang warga 
negara Belanda yang tinggal di provinsi Bali. Kasus infeksi HIV di Indonesia dilaporkan 
setiap tahunnya mengalami peningkatan dan paling banyak terjadi di usia 25-49 tahun. 
Transmisi HIV tidak mudah menular, bahkan ketika seorang yang terinfeksi HIV 
mengonsumsi obat antiretroviral dapat menurunkan risiko transmisi hingga 96%. Namun 
salah satu tantangan terbesar dalam menatalaksana infeksi HIV adalah menghadapi 
stigma dan diskriminasi. Sebanyak 1 dari 5 ODHA takut datang ke klinik dikarenakan akan 
mengalami diskriminasi dan stigma dari masyarakat apabila kondisi seperti ini terjadi 
akan menyebabkan tertundanya pengobatan hingga ODHA akan jatuh ke stadium AIDS 
dan ODHA akan rentan mengalami infeksi oportunistik. Suatu klinik di Namibia, ketika 
stigma dan diskriminasi berhasil diatasi, terjadi penurunan angka kematian pada ODHA 
sebesar 20%. 
Kata Kunci: AIDS, Diskriminasi, Infeksi HIV, Infeksi Oportunistik, Stigma 
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1 Introduction 
The case of HIV infection is one of the world's health problems. It is estimated that in 2018 
around 37.9 million people will be infected with HIV. In Indonesia, cases of HIV infection have 
increased while for AIDS cases is relatively stable. 
Acquired Immunodeficiency Syndrome (AIDS) was first recognized in 1981 when homosexual 
groups had opportunistic infections and rare malignancies [1]. On April 23, 1984, it was 
discovered that the cause of AIDS was a retrovirus called HTLV-III by Robert Gallon and tests 
for detecting HIV using the ELISA method were available in 1985 [2]. To date no country has 
been declared free from HIV / AIDS. HIV infection causes a multidimensional crisis, and this is 
because HIV infection causes an economic, development, health and education crisis [3]. 
Data from the United Nations Program on HIV / AIDS (UNAIDS) in 2018 around the world 
estimated 37.9 million people were infected with HIV, and around 770,000 people died from 
diseases that accompany HIV [4]. In Indonesia, the cumulative number of HIV infections 
reported up to June 2018 there were 301,959 inhabitants. The number of HIV cases reported 
each year continues to increase while the number of AIDS is relatively stable. This shows that 
more and more people with HIV / AIDS (PLWHA) are known to have HIV infection status and 
have not yet entered the AIDS stage [5]. 
Now HIV infection is not a death sentence like before. Antiretroviral Therapy (ART) treatment 
can provide a better chance of life and reduce the risk of HIV transmission. A study of 1763 
serodiscordant couples (one person infected with HIV and his partner not infected with HIV) 
from 9 countries, found that early ART administration could reduce the risk of HIV 
transmission by 96% [6]. Research conducted by Gueler et al involving 16,532 patients HIV 
infection from Switzerland found that life expectancy in HIV patients aged 20 years had 
increased from 11.8 years in the era of HIV monotherapy to 54.9 years in the era of HIV 
combination therapy [7]. 
2 History of HIV 
Until now it is still unknown with certainty the origin of HIV. It is suspected that the origin of 
HIV originated from the Simian Immunodeficiency virus (SIV) from primate animals (figure 1). 
Researchers suspect that SIV is transmitted to humans and mutates to HIV when humans hunt 
primates (such as chimpanzees) then eat the flesh and blood of infected animals [8]. 
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Figure 1 The origin of HIV1 
 
At the beginning of the famous case of HIV infection began in 1981. On June 5, 1981, in Los Angeles, 
there were 5 cases reported by the Centers for Diseases Control and Prevention (CDC) in young  
(previously healthy) gay men experiencing a lung infection. Pulmonary infection that is rare is 
Pneumocystis carinii pneumonia (PCP). From June 5-6 of the same year, the CDC received reports of 
similar PCP infections and opportunistic infections (including cases of Kaposi’s Sarcoma cancer) in a 
group of homosexuals. At the end of 1981, there were 270 cases of severe immune deficiency in the 
homosexual group, and 121 of them had died. Because this AIDS condition affects many homosexual 
groups, AIDS in its past was called Gay-Related Immunodeficiency (GRID) [2]. 
 
On December 10, 1982, the CDC reported cases of AIDS originating from infants who received 
blood transfusions. The following week, there were also published 22 cases of immune 
deficiency and opportunistic infections that were unexplained in infants. In May 1986, the 
International Committee on the Taxonomy of Viruses formalized the cause of AIDS is HIV [2]. 
In Indonesia, in March 1986, a case of HIV infection in Indonesia was found in a hemophilia 
patient in Cipto Mangunkusumo Hospital and was a type of non-progressor, which meant that 
the health and immunity of the patient was quite good for 17 years without treatment and had 
been confirmed by Western Blot [3]. Another case also occurred in a person who had AIDS 
found in a Dutch citizen in Bali Province in 1987, and this was the first AIDS case officially 
reported to the Ministry of Health [3, 9]. 
3 Epidemiology of HIV Infection 
In 2018, it was estimated that there are 37.9 million people infected with HIV worldwide, and 
about 1.7 million of them are new cases of HIV infection. Of 37.9 million cases of HIV in 2018, 
around 1.7 million cases were experienced in children (under the age of 15 years). Since 2010, 
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new cases of HIV infection have decreased by 16%, from 2.1 million cases to 1.7 million cases 
in 2018. Surprisingly, 8.1 million people did not know that they had been infected with HIV [4]. 
Ignorance; this will create a delay in treatment which will worsen the condition for people with 
HIV. 
In Indonesia alone, the cumulative number of HIV infections reported from 2005 up to 2019 is 
338,363 people. From January to March 2019, there were 807,488 people taking HIV tests with 
11,081 reported cases of HIV. From the Province of North Sumatra, the number of cases of HIV 
infection in March 2019 reached 522 cases [10]. Based on reports from the HIV / AIDS 
Information System (SIHA) from 2010-2019, the highest number of HIV cases were found in 
the age of 25-49 years (table 1). 
Table 1 Percentage reported HIV infection by age group from 2010-2019 [10] 
No Year  
Age group (year) 
Total  
≤ 4 % 5-14 % 15-19 % 20-24 % 25-49 % ≥50 % 
1 2010 390 1.8 405 1.9 827 3.8 3,480 16.1 15,648 72.5 841 3.9 21,591 
2 2011 547 2.6 242 1.2 683 3.2 3,113 14.8 15,490 73.7 956 4.5 21,031 
3 2012 541 2.5 208 1.0 697 3.2 2,964 13.8 15,133 70.4 1,968 9.1 21,511 
4 2013 759 2.6 316 1.1 1,058 3.6 4,493 15.5 20,976 72.2 1,435 4.9 29,037 
5 2014 1,030 3.1 358 1.1 1,101 3.4 4,894 15.0 23,512 71.9 1,816 5.6 32,711 
6 2015 795 2.6 338 1.1 1,119 3.6 4,871 15.7 21,810 70.5 2,002 6.5 30,935 
7 2016 903 2.2 406 1.0 1,510 3.7 7,154 17.3 28,602 69.3 2,675 6.5 41,250 
8 2017 901 1.9 425 0.8 1,729 3.5 8,252 17.0 33,448 69.2 3,545 7.7 48,300 
9 2018 988 2.1 459 1.8 1,434 3.1 7,068 15.1 32,847 70.4 3,863 8.3 46,659 
10 2019 195 1.8 113 1.0 261 2.4 1,678 15.1 7,843 70.8 991 8.9 11,081 
Report through SIHA as of April 15, 2019 
For AIDS cases from January to March 2019, 1,536 cases were reported. AIDS cases in 
Indonesia are relatively stable every year. AIDS cases occur in almost all occupations. In 
Indonesia in 2019, as many as 547 AIDS cases occurred in employees, followed by housewives 
in 213 cases and AIDS cases in enterpreneur as many as 174 cases [10]. 
4 HIV Infection 
HIV or Human Immunodeficiency Virus is a virus belonging to the family Retroviridae, a 
subfamily of Lentivirinae [11-13]. HIV is an ssRNA virus, enveloped, spherical, 80-100 nm in 
diameter and the HIV virion there are reverse transcriptase, protease, and integrase enzymes 
(figure 2) [11, 14]. HIV inactivation can occur if given 0.3% H2O2, 0.5% Lysol, 0.5% 
paraformaldehyde, 50% ethanol, and 35% isopropanolol. Extreme pH levels (pH 1.0 or pH 
13.0) can also inactivate HIV. Also, HIV is inactivated in a liquid heated at 56oC for 10 minutes 
[14]. 
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Figure 2 Structure of HIV.  
        
 
 
There are two HIV serotypes namely HIV-1, and HIV-2. Infection by HIV-1 is the most 
common HIV infection in the whole world, while infection by HIV-2 occurs mostly in the West 
African region [11-14]. There is a suspicion that HIV-1 originates from SIV which infects 
chimpanzees while HIV-2 derived from SIV that infects sooty mangabey [15, 16]. 
They was no idea. The condition of AIDS is rarely found in someone infected with HIV-2 so 
that the life expectancy of someone suffering from HIV-2 is longer [17]. In several studies, the 
prevalence of cases of HIV-2 infection has decreased while there has been an increase in cases 
of HIV-1 (Table 2). 
Table 2 Epidemiology comparison between HIV-1 and HIV-2 [17] 
Comparison Settings/cohort HIV-1 HIV-2 
Prevalence Gambia, 1988-2003 Increased by 4.2% in 1988-
1991 and 17.5% in 2001-
2003 
Decreased by 7.0% in 1988-
1991 and 4.0% in 2001-2003 
Prevalence and 
Incidence rate 
Guinea Bissau, 1996-
2007 
 
 
Guinea Bissau, 1990-
2007 
Increased from 2.3% in 1996 
to 4.6% in 2006; incidence 
rate of 0.5 / 100 people / year 
 
Stable: 4,5/1000 people/year 
Increased from 0.5% in 1990 
to 3.6% in 2007 
Decreased from 7.4% in 1996 
to 4.4% in 2006; incidence 
rate of 0.24 / 100 people / year 
Decreased from 4.7 to 2.0 / 
1000 people / year 
Decreased from 8.3% in 1990 
to 4.7% in 2007 
Vertical 
transmission 
Portugal, between 1999 
and 2005 Gambia 
There was a decrease from 
7% in 1999 to 0.5% in 2005 
1.5% over a 7 year period 
Risk factor 
transmission 
 24.4% transmission High 
viral load, low CD4 cell 
4.0% transmission 
Envelope surrounds a capsid that contains two identical RNA strands, 
reverse transcriptase, integrase and polymerase. The envelope spikes, 
consist of surface  (SU, gp120) and transmembrane (gp41). CA, 
capsid; MA, matrix; NC, nucleocapsid [11] 
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count, and breastfeeding High viral load, breastfeeding 
 
Various diseases can accompany someone infected with HIV. Research conducted by Ndour et 
al (2000), of 790 HIV patients with 599 cases of HIV-1 infection, 137 facts of HIV-2 disease 
and 54 cases of HIV-1 and -2 infection, found that cases such as chronic diarrhea were more 
likely to attack someone those infected with HIV-2 (83%) compared with HIV-1 (70%) and 
HIV-1, -2 (78%) infections. It is still in the same study that a person who has oral candidiasis is 
more likely to have an HIV-1 case (67%) while an HIV-2 case (58%), with the possibility of 
someone who is infected with HIV-1 being 1.46 times more likely to suffer from candidiasis 
oral [18]. Another study involving 1312 tuberculosis (TB) patients found that 241 patients were 
infected with HIV-1, 93 patients were infected with HIV-2 and 45 patients were infected with 
HIV-1, -2. From the analysis of the study, it was found that a person affected with HIV-1 had a 
six times higher risk of having TB, an HIV-2 infection had a chance of 2 times more upper, and  
HIV-1 infection, -2 a risk of 7 times higher compared to TB patients without HIV infection [19]. 
Phylogenetically HIV-1 can be divided into four groups, namely group M (major), O (outlier), 
N (non-M, non-O), and P. From group M, subdivided into 11 subtypes namely from A-K. 
Group M HIV-1 infection is predominant throughout the world, groups; O, N, and P are 
prevalent in the Cameroon region [15]. In HIV-2 it is divided into several subtypes, namely 
from A to H [11, 14, 15]. The division of these subtypes is useful to find out the distribution in 
the world and to assess the nature and behavior of viruses. So the potential for the emergence of 
drug resistance and the ability to detect HIV antibody test reagents can be known [13]. 
The HIV genome contains three main genes to form viral structural proteins, namely gag 
(specific antigen), pol (polymerase), and env (envelope). In addition there are several additional 
genes namely tat, rev, vif, vpu, vpr, and nef [12, 13, 16]. All of these genes have their respective 
roles during the process of virus replication. The function of these genes can be seen in Table 3. 
 
Table 3 Genes of HIV 11,16 
Gene Protein Size (kDa) Function 
gag p17 
p24 
p6 
p7 
p1 
p2 
 Matrix proteins, interactions with gp41 
Core protein 
Core protein, bound to vpr 
Nucleocapsid, binds to RNA 
pol Protease 
Reverse-transcriptase 
Integrase 
10 
66, 51 
32 
Proteolytic cleavage of gag and pol 
Polymerase and RNase H activity 
Integration into chromosomes 
env Gp120 
Gp 41 
 Envelope, viruses enter cells 
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Transmembrane protein, cell fusion 
tat Trans-activator of 
transcription 
14 Viral transactivator and immune suppression 
rev Regulator of expression of 
virion protein 
19 Regulates the cutting of RNA and helps move it 
to the cytoplasm 
nef Negative regulatory factor 27 CD4 downregulation; regulate the speed of virus 
replication 
vif Virion Infectivity Protein 23 Inhibits antiviral cell protein 
vpr Viral Protein R 18 Trigger viral replication in primary target cells 
vpu Viral Protein U 15-16 Triggers virion release from cells, 
downregulation of CD4 and MHC class I 
expression 
 
Infection starts with the bond between viral glycoprotein (trimer molecules of gp120 and gp41) 
with the primary receptor (CD4) and then will be tightened with one chemokine receptor 
namely CXCR4 or CCR5 which acts as a co-receptor (figure 3). These receptors and co-
receptors are found in the plasma membranes of CD4 T lymphocyte cells, monocyte cells, 
Langerhans cells, dendritic cells, and some cells in the brain [20].  
 
Figure 3 Viral binding with cell receptor. 
 
 
 
Binding with these chemokine receptors will cause cell activation and carry the viral envelope 
adjacent to the cell plasma membrane, gp41 will interact and create a fusion of the two layers. 
Immediately after the entry of the virus nucleus into the cytoplasm of infected cells, the process 
HIV spikes (gp120) binds to CD4 and chemokine co-receptor. Transmembrane 
(gp41) is responsible for fusion between viral and cell membrane [20] 
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of releasing the viral core-sheath (uncoating) and viral RNA will be converted into 
complementary DNA (cDNA) by the work of the reverse transcriptase enzyme. Then cDNA 
will be converted to double-stranded DNA (dsDNA) by the action of DNA-dependent DNA 
polymerase from the same protein reverse transcriptase. 
When dsDNA is formed, viral DNA can enter the cell nucleus through the cell nucleus pores. 
Then dsDNA is cut and introduced into cell DNA with the help of the integrase enzyme. This 
integration process requires cells when active. When integrated, viral DNA (provirus) is 
transcribed as a cell gene by the host's RNA polymerase II. This process forms the mRNA chain 
that contains the Gag, env, pol genes. Gag and pol polyproteins are cut by viral proteases 
whereas env polyproteins are cut by cellular proteases. 
The Gag polyprotein is cut to form a core protein (p24), a matrix protein (p17) and several other 
small proteins. Pol polyproteins are cut to form reverse transcriptase, integrase, and protease 
enzymes. Immature virions are composed of polyprotein precursors formed in cytoplasm and 
the process of cutting by viral proteases occurs when immature virions come out of cells so they 
can form mature (infectious) viruses [11, 20]. Illustration of the process of viral replication can 
be seen in Figure 4.  
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Figure 4 There are 7 main stages of HIV replication namely: Binding, HIV binds to its receptors 
on target cells; Fusion, HIV enters cells; Reverse Transcription, in the cytoplasm, the virus will 
use the reverse transcriptase enzyme to convert RNA into DNA so that it can enter the nucleus; 
Integration, viral DNA will join the DNA of cells; Replication, the virus will take over cells to 
make new virus components; Assembly, the components of the virus formed will be arranged into 
a complete virus; Budding, the virus (immature) will come out of the cell membrane and with the 
protease enzyme will break down the protein in the immature virus into maturity. Anti-HIV drugs 
have different mechanisms of action based on the HIV replication cycle [21] 
 
There is a uniqueness that occurs in the population of Northern Europeans who have the CCR5-
delta 32 mutation. About 1% of the Eastern European population (mainly Swedish) is 
homozygous (inherited from both parents) to this mutation. The modification of CCR5-delta 32 
will be like a "locked door" that will prevent the entry of HIV into cells. The existence of 
variations will reduce the risk of HIV transmission and slow the journey of infection to AIDS 
[11, 22]. 
5 HIV Transmission 
The highest HIV titer can be found in two body fluids, namely blood and semen. HIV 
transmission occurs through bodily fluids that contain HIV, namely through sexual contact, 
shared needles for drug users, blood transfusions, and vertical transmission from mother to baby 
[3]. Data from the Drug Dependency Hospital shows that there is an increase in cases of drug 
users living with HIV, from 16.35% in 2012 to 28.77% in 2013 [23]. About 90% of cases of 
HIV infection in children are caused by HIV transmission from mother to baby. HIV 
transmission from mother to baby through three channels namely intrauterine, intrapartum and 
through breast milk [12]. 
HIV transmission through sexual intercourse accounts for around 70% of HIV cases worldwide 
[24]. The lowest risk of HIV transmission through sexual contact is through oral sex while the 
highest is through anal sex (Table 4). A study carried out from 1990-2000 to observe the risk of 
oral sex transmission among serodiscordant heterosexual couples, found that no HIV 
transmission was recovered from an infected partner to a healthy partner [25]. There is an 
explanation of a low risk of HIV transmission through oral sex due to the presence of secreted 
enzymes leukocyte protease inhibitors (SLPI) which can interfere with the binding process of 
viruses with T cells or macrophages. Besides, other immune systems such as β-defensins, 
mucin, salivary agglutinin, and immunoglobulin A (IgA) play a role in interfering with viral 
replication [26]. 
Table 4 Estimation of possible transmission of HIV from sources of infection on various 
routes27 
Exposure Risk per-10.000 exposures 
Parenteral exposure  
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Blood transfusion 9250 
Needle sharing injection drug 
user 
63 
Percutaneous needle stick 23 
Sexual exposure  
Receptive anal intercourse 138 
Insertive anal intercourse 11 
Receptive penile-vaginal 
intercourse 
8 
Insertive penile-vaginal 
intercourse 
4 
Receptive oral sex low (0-4) 
Insertive oral sex low (0-4)  
Vertical transmission  
Mother to child transmission 2260 
 
Although the risk of HIV transmission is low through sexual intercourse, additional prevention 
is needed to suppress HIV transmission further. Antiretroviral treatment can reduce the risk of 
HIV transmission by up to 96% [6]. Other precautions such as the use of condoms, not changing 
partners, and circumcision can help prevent HIV transmission. A study involving 2784 men 
aged 18-24 years in Kenya to observe the risk of HIV transmission in circumcised men, found 
that circumcision can reduce transmission risk by 60% [28]. The same was found in research 
conducted in Africa South by involving 3274 men, that by circumcision can reduce HIV 
transmission by 60% [29]. WHO recommends considering circumcision as an HIV prevention 
effort [30]. 
There are several theories explaining circumcision that can reduce the risk of HIV transmission. 
First, the location of the superficial layer of the penis is rich in targets from HIV such as 
Langerhans cells, dendritic cells, and CD4 and CD8 lymphocytes and HIV can easily penetrate 
this layer of skin. Second, the environment of a fertile foreskin area can help the growth of 
microbes that can trigger inflammation and will invite HIV target cells to the foreskin area[31, 
32]. 
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6 HIV Infection Staging 
Without adequate treatment, sufferers of HIV infection can continue to the AIDS stage. There 
are three stages in HIV infection [33], namely: 
6.1 Stage of acute infection 
This stage is the initial stage of HIV infection and occurs within 2-4 weeks after HIV infection. 
During this stage, sufferers will experience flu-like symptoms, such as fever, headaches, sore 
throats to rashes (table 6). At this stage, the virus multiplies very quickly and spreads 
throughout the body. At this stage also the level of HIV in the blood is very high (107 particles / 
mL plasma) thereby increasing the risk of HIV transmission. CD8 T cells will kill infected cells 
and limit the production of viruses. When that happens, the level of the virus in the blood will 
decrease, and the patient will enter the chronic (asymptomatic) phase, but viral replication will 
continue within the lymph nodes causing damage to structure and function so that the number of 
CD4 T cells will continue to decline. 
Table 5 Sign and symptoms in acute HIV infection [15] 
Sign and Symptoms Percentage of patient with 
acute HIV infection 
Fever  55% 
Pharyngitis 43% 
Myalgia 39% 
Diarrhea               27% 
Limphadenopathy 36% 
Nausea 26% 
Meningismus 20% 
Headache 33% 
Photopobia 16% 
Vomitting 13% 
Rash  16% 
Oropharyngeal sores 6% 
6.2 Chronic HIV infection 
This stage is often called HIV asymptomatic infection or latent HIV infection. At this stage, 
HIV still multiplies, but its replication power decreases. At this stage, the sufferer may not 
experience symptoms but can still transmit the virus to others. At this time, the patient will 
experience an increase in viral load (viral load) and a decrease in CD4 cells. 
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6.3 Acquired Immunodeficiency Syndrome (AIDS) 
This stage is the most severe in HIV infection (figure 5). At this stage, the CD4 cell count drops 
dramatically to below 200 cells / mm3, and in AIDS conditions, it will make PLWHA easily 
susceptible to opportunistic infections. Research involving 73 PLWHA from 2007-2013 in 
Banda Aceh found that the lower the CD4 cell count, the higher the incidence of opportunistic 
infections. The results found that tuberculosis was experienced by 30 samples (20 cases were 
found at CD4 pada 49cell / mm3 levels), chronic diarrhea as many as 24 examples (9 cases were 
found at CD4≤49sel / mm3 levels) and oral candidiasis were 21 samples (13 cases were found at 
CD4 pada49 cell / mm3) level [34]. Another study conducted in Korea from 2006-2013 
involving 1086 HIV patients from 19 hospitals, found that opportunistic infections such as 
candidiasis were 176 cases (16.2% ), 121 PCP cases (11.0%), 120 TB cases (10.9%), 
cytomegalovirus infections 52 cases (4.7%), and herpes zoster 44 cases (4.0%). Cases of Kaposi 
sarcoma and toxoplasmosis were the lowest cases, which were 8 (0.7%) and 4 (0.4%) cases 
respectively [35]. 
 
Figure 5 . When first (acute) infected with HIV, virus attacks and destroys immune cells (CD4 cells); after 
this phase the virus will be suppressed by the immune system so that the speed of viral replication decreases 
(asymptomatic / chronic); many years later without anti-HIV therapy, the virus begins to make even greater 
damage to the immune system so that the levels of the immune system decrease dramatically [33] 
7 Drug Resistance 
HIV drug resistance is one or more mutations (changes) of the genetic structure of HIV that 
affects specific drugs or combinations that block viral replication. WHO classifies three ways 
that HIV drug resistance is Acquired HIV Drug Resistance (ADR), which is resistance that 
comes from someone who is taking ARV; Transmitted HIV Drug Resistance (TDR), which is 
resistance to someone who is not infected with HIV but then infected from someone who has 
HIV drug resistance; and Pretreatment of HIV Drug Resistance (PDR), which is the presence of 
viral resistance when you have previously started ARV therapy. PDR can come from ADR or 
TD [36]. 
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A review that reported genotype resistance from 9 studies from 8 countries, 4248 patients were 
evaluated. A total of 573 patients (13.5%) experienced therapy failure for 12 months. as many 
as 60% of therapy failures are due to resistance in several classes of drugs. A meta-analysis that 
represented 56,044 samples of adult patients who experienced Non-Nucleoside Reverse 
Transcriptase Inhibitor resistance (NNRTI, one of the first-line types of HIV therapy) from 63 
lower middle income countries, was estimated in 2016 of 11.0% (7.5 -15.9%) cases of 
resistance occur in South Africa, 10.1% (5.1-19.4%) in East Africa, 7.2% (2.9-16.5%) in 
Central and Central Africa , 9.4% (6.6-13.2%) in Latin America and the Caribbean, and 3.2% 
(1.8-5.6%) in Asia [37].      
HIV resistance can be caused by four factors, i.e. patient, stopping the consumption of ARV 
drugs is not what doctors recommend. This could have happened due to lack of understanding, 
side effects arising from ARV drugs; the program (government) is a challenge in country scale 
therapy. This factor concerns government relations in assisting the provision of ARV drugs; 
Therapy, inappropriate administration of treatment can increase the risk of ARV drug resistance. 
Fortunately, a fixed-dose combination drug is now available (in one drug consisting of several 
different medications), with this therapy, it is hoped that it can improve patient compliance with 
antiretroviral treatment; and viruses, the high speed of virus replication can enable the formation 
of new HIV subtypes that have the possibility of ARV resistance [38]. 
With the emergence of ARV resistance cases, it is expected to increase vigilance in handling 
cases of HIV infection. If HIV infection is accompanied by antiretroviral resistance this can 
disrupt immune system repair, decrease the effect of the work of antiretroviral drugs to increase 
mortality [39]. 
8 Stigma and Discrimination 
Someone infected with HIV often experiences acts of stigma and discrimination. Recently 
discrimination was experienced by 14 elementary school students in Solo who were infected 
with HIV, and they were condemned by other parents of students to be expelled from their 
schools for fear of transmitting the disease to other healthy children [40]. Overseas, acts of 
discrimination were also experienced by someone infected with HIV. "My daughter refused to 
go to the hospital to get treatment. My daughter died because of fear of stigma and 
discrimination that was labelled by the community ". The sentence was said by a grandmother 
from Ghana who lost her daughter who is also a PLWHA [41]. 
A study involving data from 19 countries revealed that 1 in 5 (20%) PLWHA were afraid of 
coming to the clinic because of the stigma and discrimination they received in the community 
[39]. If this stigma and discrimination were allowed to occur, this would result in delays in 
treatment of PLWHA and this will worsen the health condition of PLWHA. In a clinic in 
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Namibia when stigma and discrimination were successfully eliminated, there was a 20% 
reduction in the mortality rate for people with HIV [42]. This decrease was due to the 
emergence of awareness and support from the public regarding the importance of treatment for 
PLWHA. 
9 Conclusion 
Since the discovery of the first case of HIV with opportunistic infections, until now, HIV 
infection is a severe health problem worldwide. HIV infection, also, to interfere with health, will 
disrupt the psychological sufferers. This is due to the stigma and discrimination they get from 
the community. If this stigma and discrimination are left unchecked, it will cause a person who 
is infected with HIV to delay treatment, and this will cause the condition of AIDS so that 
PLWHA more easily experience opportunistic infections. With the elimination of stigma and 
discrimination will help reduce mortality rates for PLWHA. 
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